Information Provided By: 
Fly News Breaks for May 25, 2017
PBYI
May 25, 2017 | 07:34 EDT
As previously reported, Cowen analyst Chris Shibutani upgraded Puma Biotechnology to Outperform from Market Perform. The analyst cited the positive FDA AdCom review and its anticipated approval for its breast cancer drug in July. The panel's positive review removed the key risk underlying his previous recommendation and the company presentation and straightforward analysis by the FDA, provided enough clarity to warrant the upgrade. Shibutani has a $91 price target on Puma Biotechnology shares.
News For PBYI From the Last 2 Days
There are no results for your query PBYI
